Defining Responses to Therapy and Study Outcomes in Clinical Trials of Invasive Fungal Diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer Consensus Criteria
Top Cited Papers
- 1 September 2008
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 47 (5), 674-683
- https://doi.org/10.1086/590566
Abstract
Invasive fungal diseases (IFDs) have become major causes of morbidity and mortality among highly immunocompromised patients. Authoritative consensus criteria to diagnose IFD have been useful in establishing eligibility criteria for antifungal trials. There is an important need for generation of consensus definitions of outcomes of IFD that will form a standard for evaluating treatment success and failure in clinical trials. Therefore, an expert international panel consisting of the Mycoses Study Group and the European Organization for Research and Treatment of Cancer was convened to propose guidelines for assessing treatment responses in clinical trials of IFDs and for defining study outcomes. Major fungal diseases that are discussed include invasive disease due to Candida species, Aspergillus species and other molds, Cryptococcus neoformans, Histoplasma capsulatum, and Coccidioides immitis. We also discuss potential pitfalls in assessing outcome, such as conflicting clinical, radiological, and/or mycological data and gaps in knowledge.Keywords
This publication has 76 references indexed in Scilit:
- Caspofungin Modulates Inflammatory Responses toAspergillus fumigatusthrough Stage‐Specific Effects on Fungal β‐Glucan ExposureThe Journal of Infectious Diseases, 2008
- Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus GroupClinical Infectious Diseases, 2008
- Editorial Commentary:Learning from Our Failures: The Antifungal Treatment ConundrumClinical Infectious Diseases, 2008
- Trial Design for Mold-Active Agents: Time to Break the Mold--Aspergillosis in Neutropenic AdultsClinical Infectious Diseases, 2007
- Pretreatment with Empty Liposomes Attenuates the Immunopathology of Invasive Pulmonary Aspergillosis in Corticosteroid-Immunosuppressed MiceAntimicrobial Agents and Chemotherapy, 2007
- A Drug-Sensitive Genetic Network Masks Fungi from the Immune SystemPLoS Pathogens, 2006
- The Role of Immune Reconstitution Inflammatory Syndrome in AIDS‐RelatedCryptococcus neoformansDisease in the Era of Highly Active Antiretroviral TherapyClinical Infectious Diseases, 2005
- Infusion‐related toxicity of three different amphotericin B formulations and its relation to cytokine plasma levelsMycoses, 1995
- Itraconazole therapy for nonmeningeal coccidioidomycosis: Clinical and laboratory observationsJournal of the American Academy of Dermatology, 1990
- Miconazole in the Treatment of CoccidioidomycosisDrugs, 1983